Camp4 Therapeutics Corp (CAMP) Stock Profile — Insider Trades & Financials

Revenue$348.0K

Net Income-$40.3M

EPS$-1.78

Market Cap$237.8M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Joshua Mandel-Brehm

CEO & Executive Director

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Founded: 2016
Employees: 48
Headquarters: Cambridge, Massachusetts, United States

⚡

Core Efficiency

ROE?

-84.45%

ROA?

-34.19%

D/E Ratio?

1.47

Op. Margin?

-3671.26%

📊

Profitability Ratios

Net Margin?

-11575.86%

Loading company sections...

Camp4 Therapeutics Corp

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness